

VPRS Administrative Updates September 27, 2022

Agenda

- ORA Leadership Updates
- ORA Post-Award Restructure
- Ancillary Review Reminders
- IBISResearch Proposal Information Accuracy
- Jackson ONENESS Update
- Grants.gov Unavailable
- NIH Forms E and H
- Research.gov Updates
- Award Close Out Time Frame Reminders
- RQA Transition
- New IRB system
- AAHRPP reaccreditation update/upcoming site visit
- Huron Solutions & New Intake Report Form
- Increased Enforcement by FDA and NIH
- Civil Penalties Assessed by FDA



ORA Leadership Updates

Laura Kozma

Associate Vice President Research Administration

Edwin Bemmel Leaving UM

- Edwin Bemmel, Executive Director of Research Administration who leads Post-Award has accepted a position as Associate Vice President, Research, Grants and Contracts at Emory University.
- Effective immediately, list "Laura Kozma, Associate Vice President, Research Administration" as the Financial Officer on all documents where Edwin would normally be listed.
- If you have any questions or concerns, please contact me (<u>lkozma@miami.edu</u>).

IVERSITY MIAMI



Edwin Bemmel Executive Director, Research Administration





ORA Post-Award Restructure

Laura Kozma

Associate Vice President Research Administration

ORA Post-Award Restructure





UNIVERSITY OF MIAMI



Ancillary Review Reminders

Laura Kozma

Associate Vice President Research Administration

Ancillary Review Reminders

- Make sure you are sending to the right person
- Include all relevant documents (cost sharing form, supporting letters, etc.)
- Route early!



This job aid provides information on how to submit an ancillary review in IBISResearch. How to Submit an Ancillary Review > Ancillary Review Guide > Ancillary Review Matrix > F&A Waiver/Cost Share Form >

Ancillary Review Type	Initiator	Approver	Response Required?	Required Documents/Information	Person or Organization	Selection
Compliance (COI)	ORA	VPR/EDR	Y	Read and follow the <u>Conflict of Interest in Research</u> Policy. Include a letter disclosing the potential conflict Attach to Ancillary Review	N/A	This is for SBIR/STTR only and generated by ORA.
Cost Share	Department	VPR/EDR	Y	Read and follow the <u>Cost Sharing Policy</u> . Cost <u>Sharing Policy</u> . <u>Justification letter for the Cost Share</u> <u>NEW REQURED: Cost Share Form</u> <u>NEW REQURED: Cost Share Form</u> <u>Share</u> <u>Went are briefed or attributions</u> <u>Attribution Share</u> <u>Share</u> <u>Attribution</u> <u>Share</u> <u>Went and the scheded or attribution</u> <u>attribution</u> <u>Share</u> <u>Attribution</u> <u>attribution</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>attribution</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>attribution</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u> <u>Share</u>	Person	<u>Gables or RSMAS;</u> Laura Kozma <u>Medical:</u> Patricia Wahi for Dr. Schulman
Department Chair/Center Director (as PI)	Department	Dean/Dean Designee	Y	Include a justification comment for approval in the ancillary review. Note: if an approver noted here is the Pi, the Proposal requires approved from a higher level.	Person	Medical: Carl Schulman <u>RSMAS</u> : Roni Avissar <u>A&S</u> : Leonidas Bachas <u>Engineering</u> : Fabrice Manns
Export Controls	Department/ORA	William Collins	Y	Read and follow the <u>Export Control Policy</u> . Letter disclosing export control concerns Attach to Ancillary Review	Person	William (Bill) Collins
Indirect Cost Waiver	Department	VPR/EDR	Y	Read and follow the <u>F&A Waiver Policy</u> . Justification letter NEW REQUIRED: <u>Indirect Cost Waiver Form</u> (must be included on attachments)	Person	Gables or RSMAS: "Provosts Office" (CC00372) on the Organization Medical: Carl Schulman
Late Proposal Submission	Department	VPR/EDR	Y	Required documents/Information: Read and follow the <u>Proposal Exception Process</u> Include a justification and supporting documentation Request must be submitted <u>in advance</u> of the ORA deadline	Person	Medical, Gables and <u>RSMAS</u> : Laura Kozma
Nepotism/Familial Relationship	Department	VPR/EDR	Y	Read and follow the <u>Nepotism in Research Policy</u> . Include a Nepotism Memo Attach to Ancillary Review	Person	Medical, Gables and <u>RSMAS</u> : Laura Kozma

BISResearch

https://www.research.miami.edu/systems/education-and-resources/job-aids/indexhtml

Last Revised: 06/01/22

Ancillary Review Matrix Grants




IBISResearch Proposal Information Accuracy

Laura Kozma

Associate Vice President Research Administration

IBISResearch Proposal Information Accuracy

- Accurate data is everyone's responsibility
- Review prior to submitting to ORA
- Consult with the PI
- Inform ORA of inaccurate data







Jackson ONENESS Update

Laura Kozma

Associate Vice President Research Administration

Jackson ONENESS Update



ONENESS


Mission Statement To advance research through a collaborative effort, built on a shared foundation of diverse and unique patient data and resources integral to the broader missions of UHealth and JHS.



Clinical Research Workgroup



Reduce Turnaround Times





- Taskforce created
- End to end process documentation
- Initiatives identified

 UM reorganization of contracting team
 Inclusion of UM in CRRC

VERSITY

Current Initiatives

	ClickUp	Provide transparency about the status of clinical trials pending activation at JHS by implementing a software solution	
Short Term	Confidentiality Agreements	Leverage the master agreement to reduce the number of confidentiality agreements required	
	UM Budget Structure	Evaluate and reorganize the budget team at UM to streamline budget and coverage analysis development	
	DEF Initial Streamline	Complete DEF process in parallel with existing processes to reduce burden	
Medium Term	Signature Process	Review and streamline signature process	
	Regulation Alignment	Determine where UM and JHS are not aligned on interpretation of regulations, draft position papers and agree on interpretation	
Long Term	Single Budget Development	Create budget and coverage analysis as a single unit utilizing master rate sheets and unified decision making	
	DEF Overhaul	Evaluate current master agreement, needs of each institution to eliminate all unnecessary steps, amend the master agreement and streamline process	
	Feasibility	Create JHS feasibility review utilizing CRRC and new budget process to decrease review turnaround times	

$\begin{bmatrix} \\ \end{bmatrix}$

Administrative Updates

Tonya Sautier Sr. Business Officer, Finance and Administration, OVPRS

New Hires

Name	Title
Amanda Monzon	Bookkeeper
	Notion Welkow We





ORA Leadership Updates

K. Brandon Strickland, J.D. *Executive Director, Research Administration*

Brandon Strickland New Hires

Name	Title
Evgueni Trepaline	Contract and Grants Analyst
Jairo Lazo	Contract and Grants Analyst
Eliana Valdes	Contract and Grants Analyst
Amy Gonzales	Contract and Grants Analyst
Leydis Sales	Contract and Grants Officer
Holly Kasem-Beg	Associate Director Research Administration
Deborah Musgrove	Associate Director Research Administration

Departures

Name	Title
Alonso Antunez de Mayolo Cristina Serafini Magalys Hernandez Marco Chin	Contract and Grants Analyst Contract and Grants Officer Contract and Grants Analyst



UNIVERSITY



Grants.gov Unavailable

K. Brandon Strickland, J.D. *Executive Director, Research Administration*

Grants.gov Unavailable

- Planned outage: September 23, 2022 at 12:01 AM ET to September 29, 2022 at 11:59 PM ET.
- Consider this when planning a proposal submission through Grants.gov.
- During the outage you will not be able to create a new proposal for S2S submissions
- Work can be continued on proposals where the FOAs were downloaded prior to Grants.gov outage, but the proposal must be created with the FOA prior to the downtime
- NIH and AHRQ due dates that fall on or between September 22 and September 30, 2022 will move to October 3, 2022.

MIAMI



Grants.gov Unavailable

Grants.gov Cloud Migration

Overview

U	U	I
Н		

Training environment downtime: August 30 – September 19, 2022

Production environment downtime: September 23 – 29, 2022

Grants.gov's maintenance schedule is available here: https://www.grants.gov/web/grants/support/calendar.html

- Grants.gov's cloud migration is part of a 4 5 year effort to modernize the Grants.gov system.
 - After successful migration, Grants.gov will focus efforts on:

UI updates that support a modern and responsive design driven by human centered activities

□ Redesign web services to transition to REST API from SOAP services (targeting 2023)

 Grants.gov has been providing updates about the cloud migration and system downtime to the Applicant and Grantor communities through listservs, the <u>Grants.gov blog</u>, and banners on the Grants.gov site.



Grants.gov Cloud Migration

Grants.Gov Cloud Migration

Impact to SF424 and other systems connecting to Grants.gov

- X Users will not be able to do the following during the Grants.gov downtime:
 - Download or update FOAs
 - Submit SF424 applications
 - Retrieve status updates on submitted applications
- ✓ Users will be able to do the following during the Grants.gov downtime:
 - Create SF424 applications from FOAs that were downloaded prior to the Grants.gov system going offline
 - Edit existing SF424 applications
 - Validate SF424 applications
 - Generate the PDF for SF424 applications

Grants.gov Cloud Migration

Grants.Gov Cloud Migration

Questions from the community

- Q If a user starts an application prior to the Grants.gov system going offline, will the data still be available when the system comes back online?
 - A Yes, the data will still be available as it is entered, edited, and stored in the Huron system, not the Grants.gov system.
- Q If an SF424 application is submitted before the downtime, will the application remain intact when the system comes back online?
 - A Yes, the reason that Grants.gov will be down for the extended period of time is to ensure that everything migrates over successfully.
- Q If something happens and the application is lost, how will users be able to tell, and will the applications be allowed to be submitted again without penalty?
 - A If there is a problem with an application related to the migration, users will need to contact the Grants.gov and federal agency help desks for guidance on what steps to take next.



Grants.gov Cloud Migration

Grants.Gov Cloud Migration

Questions from the community (continued)

- Q Have agencies besides NIH extended their deadlines for submissions that have deadlines during the downtime?
 - A Grants.gov has been reaching out to the agencies to inform them of the downtime so that they can adjust their deadlines if they fall within the migration period, but there is not a list of agencies contacted or a list of adjusted deadlines available.



NIH Forms E and E


K. Brandon Strickland, J.D. *Executive Director, Research Administration*

OF MIAMI

NIH Adjusted Deadlines

NIH Adjusted Deadlines

Overview



Guidance for adjusted deadlines can be found here: <u>https://nexus.od.nih.gov/all/2022/08/03/extended-grants-gov-downtime-impacts-september-22-</u> 30-due-dates/

- NIH has adjusted due dates that fall during the Grants.gov migration period, September 22-29, 2022, to an extended due date of October 3, 2022.
- Be sure to read the NIH announcements regarding the Grants.gov downtime and the extended due date as there are caveats.



NIH Forms H Update

NIH FORMS-H Update

Overview



NIH will begin posting FORMS-H application packages **October 25, 2022**, for submissions due on or after January 25, 2023

Details for NIH FORMS-H can be found here: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-195.html

- The FORMS-H update is being implemented to support the 2023 NIH Data Management and Sharing Policy. You can find details about this policy here: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-013.html
- During the transition period from FORMS-G to FORMS-H, both sets of forms will be active, and the user will need to select the correct form set based on the due date for the opportunity.
 - For due dates before January 25, 2023, use FORMS-G application packages
 - For due dates on or after January 25, 2023, use FORMS-H

TITICTT

NIH Forms H Update

NIH FORMS-H Update

Impact to SF424

- SF424 will need to be upgraded to SF424 10.5.0 and 10.5.1
 - SF424 10.5.0 will include the following updated forms:
 - PHS Career Development Award Supplemental Form V6.0
 - PHS 398 Research Plan V5.0
 - PHS 398 Research Training Program Plan V5.0
 - PHS Fellowship Supplemental Form V7.0
 - SF424 10.5.1 will include the following updates:
 - Updates to the forms where only the OMB expiration date is being updated (waiting on OMB approval). See https://grants.nih.gov/grants/electronicreceipt/files/high-level-form-change-summary-FORMS-H.pdf for a high-level summary of changes to the forms.
 - Text updates to the following forms:
 - PHS Cover Page Supplement V5.0
 - PHS 398 Modular Budget V1.2

NIH Forms Retirement Update

NIH Forms Retirement Update

Overview



NIH will retire form versions prior to FORMS-E in ASSIST on August 31, 2022

Details for the retirement of these forms can be found here: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-182.html

- Form versions prior to FORMS-E will be retired in ASSIST as the government has fully transitioned from DUNS to UFL
- Applicants will not be able to copy data from retired form versions to applications that use active FORMS-G forms.





Research.gov Updates

K. Brandon Strickland, J.D. *Executive Director, Research Administration*

Overview



Grants.gov integration will migrate from Fastlane to Research.gov on October 31, 2022.

Last day to submit new proposals in Fastlane will be **January 27, 2023**.

Last day to submit proposal file updates, budget revisions, or download submitted proposals in Fastlane will be **September 29, 2023**.

- NSF is in the final phases of fully transitioning to Research.gov and retiring Fastlane.
- Fastlane will be removed as a submission option in all solicitations in January 2023.
- Applications submitted through Grants.gov will begin going to Research.gov instead of Fastlane.



Grants.gov integration

- Proposals submitted through Grants.gov on or after October 31, 2022, will be available in Research.gov for file updates and budget revisions.
- Proposals submitted through Grants.gov prior to October 31, 2022, will be available in Fastlane for file updates and budget revisions until September 29, 2023.
- NSF will continue to pick up applications from Grants.gov every 5 minutes.
- Submissions through Grants.gov will go through the following 3 steps:
 - Data will be converted to data elements accepted by Research.gov.
 - Data will go through a pre-check process.
 - Data will go through a post-check process.



Grants.gov integration pre-check process

- The pre-check process checks for the minimum requirements to be accepted in the Research.gov system.
 - If the application does not pass the pre-check process, the applicant will be notified by email and will be required to correct the application in the source system (Huron SF424, Grants.gov, etc.) and then resubmit the application.
- The pre-check process checks for the following:
 - If the FOA has a due date more than 1 year from the current date.
 - If the FOA is on the solicitation exclusion list for Research.gov.
 - If the solicitation has multiple UOCs and a UOC is incorrect. If there is only one UOC, the system will auto-correct the UOC.
 - If the UEI entered for the primary organization is not valid.
 - If the NSF ID for the PI is not valid.



Grants.gov integration pre-check process

- The pre-check process checks for the following (continued):
 - If prime organization is a P-type institution, but the proposal type is not Fellowship or if the prime organization is not a P-type institution, but the proposal type is Fellowship.
 - If the zip file received from Grants.gov is empty or has any attachments that are 0 bytes.
 - If the zip file received from Grants.gov fails to open.
 - If the zip file cannot be retrieved from Grants.gov.
 - If the XML is malformed, the data mapping cannot be completed.



Grants.gov integration post-check process

- The post-check process happens when the application has passed the pre-check process and checks for Research.gov compliance validations.
 - If the application does not pass the post-check process, the PI, SPO, and AOR will be notified by email and the submitting organization will be required to correct the application in Research.gov and then resubmit the application.
 - An application that fails the post-check process can be found in the in-progress list in Research.gov and will be considered as a pending submission.
- The post-check process checks for the following:
 - If the application fails any of the validations in the current validations found here:

https://www.nsf.gov/bfa/dias/policy/autocompliance.jsp

- If FOA has the nearest due date that is in the past.



NSF Fastlane to Research.gov Transition

Email notifications for Grants.gov submissions

- NSF will send the following email notification for a successful submission:
 - Subject line will be "Proposal XXXXX Submitted" and the notification will include the following details.
 - Confirmation that the submission was successful with proposal number
 - Grants.gov ID
 - Date/time of submission
 - Proposal title
 - Date/time received by NSF
 - Organization
 - SAM legal business name
 - Guidance on where to access the application
 - This email notification will be sent to the PI, co-PI(s), OAU(s), AOR associated with the prime organization.



NIVERSITY

NSF Fastlane to Research.gov Transition

Email notifications for Grants.gov submissions

- NSF will send the following email notification for a submission that does not pass the pre-check process:
 - Subject line will be "Proposal Errors Need Correction in Grants.gov" and will include the following details.
 - Grants.gov ID
 - Date/time of submission
 - Errors that need to be corrected
 - If you receive a notification with the subject line "Proposal Errors Need Correction in Grants.gov, you will need to make your corrections in the source system that submission originated from.
 - This email notification will be sent to the PI email that corresponds with the NSF ID. If the NSF ID is not valid, the email notification will be sent to the email address for the PI in the SF424 (R&R) form.



NSF Fastlane to Research.gov Transition

Email notifications for Grants.gov submissions

- NSF will send the following email notification for a submission that does not pass the post-check process:
 - Subject line will be "Proposal Errors Need Correction in Research.gov" and will include the following details.
 - Grants.gov ID
 - Date/time of submission
 - Temporary ID number
 - Proposal title
 - Organization
 - SAM legal business name
 - Guidance on where to access the application
 - Errors that need to be corrected
 - If you receive a notification with the subject line "Proposal Errors Need Correction in Research.gov, you will need to make your corrections in Research.gov.
 - This email notification will be sent to the PI, SPO associated with the primary organization, and the AOR associated with the primary organization.

UNIVERSITY



Administrative Updates

Edwin Bemmel Executive Director, Research Administration

Edwin Bemmel New Hires

Name	Title
Andres Quinta	Sr. Grant Assistant
Stacy Machado	Grant Accountant
Tatyana Dauphin	Sr. Grant Assistant
Xiomara Morales	Grant Accountant





Edwin Bemmel Promotions

Name	Title
Ania Cabrera	Sr. Grant Accountant
Isabel Samper	Grant Accountant
Veronica Wong	Sr. Grant Accountant
OF MIAMI	



Award Close Out Time Frame Reminders

Edwin Bemmel Executive Director, Research Administration

Award Close Out Time Frame Reminders

Deadline Timeline

Direct federal (includes all awards where the funding is provided from the federal agency to the University):

	Financial Reporting and Invoice Due Date:	Department close out:	ORA sub	mission deadline date:
	120 days after award/budget end date	60 days after award	90 days	after award/budget end date
1	All non federal, and federal funding provided to the	e University through a subaw	/ard:	
	Financial Reporting and Invoice Due Date:	Department close out:		ORA submission deadline date:
	>60 days after award/budget end date	30 days after award/budget (date	60 days after award/budget end date
	60 days after award/budget end date	30 days after award/budget (date	45 days after award/budget end date
	45 days after award/budget end date	15 days after award/budget d	late	30 days after award/budget end date
UNIVERSITY OF MIAMI	30 days after award/budget end date	15 days after award/budget d	late	21 days after award/budget end date



Administrative Updates

Mikki O'Neal Associate Vice President, Research Operations & Infrastructure

New Hires

Name	Title
Alejandra Quinones	Project Manager



Promotions

Name	Title
Daniel Auguste	Data Management Coordinator
Kanchan Sakhrani	Sr. Business Systems Analyst
Kristine Martinez	Sr. Project Manager
UNIVERSITY	



Departures

Name	Title
Allen Mora	Executive Director, Research Intelligence & Capacity (RIC)
Leah Bamford	Project Manager





RQA Transition

Scott Streibich Executive Director, Research



UNIVERSITY

RESEARCH COMPLIANCE AND QUALITY ASSURANCE

is changing



RQA Transition

From September 27th onward

RESEARCH QUALITY ASSURANCE




Research Quality Assurance

- Reporting structure now under Research Operations and Infrastructure
- Quality Reviews Continue Unchanged
- Continuous Quality Improvement supports Collegiality and Collaboration
- Participant Safety during research conduct is still paramount
- "Partners, Not Police"
- Focus on Leveraging Data to Educate and Support GCP
- Collaboration for Continuous Improvement
 - RQA alongside study teams
 - CAPA Facilitation
 - Study Improvement Tools (e.g. Study Conduct Checklist)

UNIVERSITY OF MIAMI

Research Quality Assurance





Administrative Updates

Kenia Viamonte Director, Human Subject Research (HSRO)

Promotions

Name	Title				
Denise Dimitriu	IRB Regulatory Analyst				
Di Ding	Sr. Manager, Research Support				
Karen Legagneur	Sr. IRB Regulatory Analyst				
Karla Fongyee	Sr. IRB Regulatory Analyst				
Vivienne Carrasco	Associate Director, Regulatory Affairs				
Yaslaime Fraga	IRB Regulatory Analyst				
Anthony Fernandez	Sr. IRB Regulatory Analyst Promotion				
Angel Gallusi	IRB Regulatory Analyst				



New IRB System

Kenia Viamonte Director, Human Subject Research (HSRO)

UNIVERSITY OF MIAMI



New IRB System

Purpose of re-implementation: To continue to enhance the University's commitment to a comprehensive Research Administrative System. IBISResearch was expanded to include the re-implementation of the *IRB system with a soft go live on 8/12/2022 and official go live on 8/29/2022*. [Access to the legacy system read-only]

Benefits:

✓ Integration with the other research solutions Grants, Agreements, Udisclose

- ✓ Reduced administrative burden
- ✓ Intuitive and simplified smart forms for submissions

Current Project Phase - Stabilization:

✓ Issue resolution ongoing (i.e., visibility to studies)

✓ Operational report build

✓IRB system enhancements (i.e. new research billing question)

✓IRB-Velos integration re-implementation go live 9/10/2022

UNIVERSITY OF MIAMI

New IRB System

To learn more about the IRB system such as system access, training material, new features, visit the OVPRS IBISResearch website: <u>https://hsro.uresearch.miami.edu/researchers/irb-system-upgrade/index.html</u>

For Support:

- Human Subjects Research Office (305-243-3195; hsro@miami.edu)
- OVPRS Help Desk (305-243-2314; <u>OVPRShelpdesk@miami.edu</u>)







AAHRPP Reaccreditation Update/Upcoming site visit

Kenia Viamonte Director, Human Subject Research (HSRO)

AAHRPP Reaccreditation Update

Step 1 – of application was approved with (0) revisions
Step 2 – was submitted; now only pending site visit scheduling

Site visit – anticipated for early 2023



Association for the Accreditation of Human Research Protection Programs, Inc.®



Upcoming Site Visit

The accreditation process is an institution wide initiative

The site visit, specifically, draws in key partners from all areas of our Human Research Protection Program (HRPP)

- Communication, preparation and training materials
- Responsibilities are grouped by Domain

What makes it all come together is our mutual commitment and dedication to our mission and to our program. THANK YOU!



Huron Solutions and New Intake Report Form

UNIVERSITY OF MIAMI



Raquel Zamora/Kristine Martinez Sr. Manager IT, Sr. Project Manager



What's Next?

- Grants upgrade in the new year
- IACUC Implementation, target go live July '23
- Animal Operations Implementation, target go live April '24



New Intake Report Request Form

Purpose: This form is to be used to submit research report requests to the Office of the Vice Provost for Research and Scholarship.

Benefits: Report requests processed centrally by the team who serve as data custodians and knowledge experts of research applications (i.e., IBISResearch Grants, IRB, UDisclose, Velos), who also work intimately with the business system owners for accuracy and integrity of data delivered.

Where:

- Information Technology Self-Service Portal
 - Order Items and Services
 - Click on the Office of Research and Scholarship Data/Report Request (OVPRS)



Administrative Updates

Yolanda Davis Director, Clinical Research OVPRS

New Hires

Name	Title
Letty Ginsburg	Manager, Clinical Research, Clinical Research Management and Support Office (CRMSO)
	Wolkow We
	Valkommen Tuloy ka Velkomen Viej viej viej Bienvenge Mituvina suklub State Horas Been Vindo Been Vindo Bienvenge Velkomen Tuloy viej Bienvenge Velkomen Tuloy viej Bienvenge Bie
UNIVERSITY	



Increased Enforcement by FDA & NIH

Non-Compliance of ClinicalTrials.gov Records

Yolanda Davis Director, Clinical Research OVPRS

FDA Requirements

- Register Applicable Clinical Trials (ACT) within 21 days of enrollment of the first participant
- Updating your ClinicalTrials.gov record within 30 days of any of the below occurring.
 - Change in responsible party (contact information, official title or the name of the individual)
 - Change in overall recruitment status
 - Change in study start date, study primary completion date, and study completion date
 - Human Subject Review Board Status
 - Name of Intervention
- Report Results for ACTs within 12 months of the last participant reaching the primary completion Date



FDA Enforcement



NOTICE OF NONCOMPLIANCE ISSUED PURSUANT TO 42 U.S.C. 282(j)(5)(C)(ii)

VIA UNITED PARCEL SERVICE

July 26, 2021

Accuitis, Inc. Attention: Rick Coulon 1005 Alderman Drive, #104 Alpharetta, Georgia 30005

Accuitis, Inc. Attention: Rick Coulon 150 Technology Parkway, Suite 173 Peachtree Corners, GA 30092

> Re: Notice of Noncompliance with the Requirements for Submission of Clinical Trial Results Information for "Efficacy of ACU-D1 in the Treatment of Acne Rosacea" (NCT 03064438) FDA Reference Number: CDER-2021-105

Dear Mr. Coulon:

The United States Food and Drug Administration (FDA) sent you a letter dated October 26, 2020, alerting you to potential noncompliance with the requirement to submit clinical trial results information to the ClinicalTrials.gov data bank operated by the National Library of Medicine (a part of the National Institutes of Health) for the above-referenced clinical trial. Accuitis, Inc., is the "responsible party"¹ for the above-referenced clinical trial, which is an "applicable clinical trial"² that is subject to the requirements of section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), including its implementing regulations in 42 CFR part 11. A responsible party for an applicable clinical trial is required to submit to the ClinicalTrials.gov data bank certain results information generally must be submitted no later than one year after the primary completion date of the applicable clinical trial, unless the responsible party has submitted a



NOTICE OF NONCOMPLIANCE ISSUED PURSUANT TO 42 U.S.C. 282(j)(5)(C)(ii)

VIA UNITED PARCEL SERVICE AND E-MAIL

August 31, 2021

Andrey Petrikovets, M.D. 1513 South Grand Avenue, Suite 400 Los Angeles, California 90015

Re: Notice of Noncompliance with the Requirements for Submission of Clinical Trial Results Information for "ICE-T Postoperative Multimodal Pain Regimen Compared to the Standard Regimen in Same Day Vaginal Pelvic Reconstructive Surgery: A Randomized Controlled Trial" (NCT03052816) FDA Reference Number: CDER-2020-109

Dear Dr. Petrikovets:

The U.S. Food and Drug Administration (FDA) sent you a letter dated July 20, 2020, alerting you to potential noncompliance with the requirement to submit clinical trial results information to the ClinicalTrials.gov data bank, operated by the National Library of Medicine (a part of the National Institutes of Health), for the above-referenced clinical trial. You are the "responsible party"¹ for the above-referenced clinical trial, which is an "applicable clinical trial"² that is subject to the requirements in section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), including its implementing regulations in 42 CFR part 11. A responsible party for an applicable clinical trial is required to submit to the ClinicalTrials.gov data bank certain results information for the clinical trial; such results information generally must be submitted no later than one year after the primary completion date of the applicable clinical trial, unless the responsible party has submitted a certification of delay, a request for an extension of good cause, or a request for a waiver of the requirements for submission of results information.³

In our previous letter, we requested that you review your records for this clinical trial and submit all required results information promptly. We also stated that we intended to further review and assess this clinical trial beginning 30 calendar days after you received our previous letter, and that we might take regulatory action if we determined that you were not in compliance at that time.

¹ See section 402(j)(1)(A)(ix) of the Public Health Service Act (PHS Act) (42 U.S.C. 282(j)(1)(A)(ix)) and 42 CFR 11.10 for the definition of "responsible party."

² See section 402(j)(1)(A)(i)-(iii) of the PHS Act (42 U.S.C. 282(j)(1)(A)(i)-(iii)) and 42 CFR 11.10 for the definition of "applicable clinical trial."

¹ See section 402(j)(1)(A)(ix) of the Public Health Service Act (PHS Act) (42 U.S.C. 282(j)(1)(A)(ix)) and 42 CFR 11.10 for the definition of "responsible party."

² See section 402(j)(1)(Å)(i)-(iii) of the PHS Act (42 U.S.C. 282(j)(1)(Å)(i)-(iii)) and 42 CFR 11.10 for the definition of "applicable clinical trial."

³ See section 402(j)(3)(E) of the PHS Act (42 U.S.C. 282(j)(3)(E)) and (H)) and 42 CFR part 11, subpart C for results submission requirements.

• All of the FDA requirements plus

 Registration of all federally funded studies that meet the below definition

A research study in which one or more human subjects are <u>prospectively assigned</u> to one or more <u>interventions</u> (which may include placebo or other control) to evaluate the effects of those interventions on <u>health-related biomedical or behavioral outcomes.</u>



NIH Enforcement

DEPARTMENT OF HEALTH & HUMAN SERVICES National Institutes of Health Bethesda, Maryland 20892	
March 23, 2018 To: V. Whittemore, Program Officer From: E. R. Rosenberg	Date: July 18, 2022 at 6:51:43 PM GMT+5:30 Cc: ORA Award < <u>Nihaward@med.miami.edu</u> >, "NIDDK DK eRA Notifications (NIH/NIDDK)" < <u>dkeranotifications@niddk.nih.gov</u> >, "Gunter, Tommy (NIH/NIDDK) [E]" < <u>tommy.gunter@nih.gov</u> > Subject: [EXTERNAL] Re
RE: Grant #	CAUTION: This email originated from outside the organization. DO NOT CLICK ON LINKS or OPEN ATTACHMENTS you know and trust the sender.
All National Institutes of Health funded clinical trials are to provide information to the public through the <u>ClinicalTrials gov</u> web site, and keep their study details updated concluding with study final results submission (<u>link to policy</u>). To this end, the National Institutes of Neurologic Disease and Stroke (NINDS) conducts a quarterly database review of its funded trials for compliance. During this review, the trial associated with grant identified above, was found to be out of compliance. You are asked to open the page to update the status and add the findings if the study is closed.	Some of the Information provided in your RPPR on the study (Enrollment of the first subject (Study Start Date)) does not match the information in Clinicaltrials.gov for the Clinicaltrials.gov identifier provided Please correct this at your earliest convenience in order not to delay the issuance of your award. Thank you. ziya
If there are questions about accessing your page for updating the information, refer to the National Library of Medicine's "frequently asked questions for Investigators" (<u>ClinicalTrials.gov link</u>), or contact the customer support (<u>register@clinicaltrials.gov</u>). For questions related to the quarterly review, contact this office at <u>rosenbeel@nih.gov</u> .	Ziya Kirkali, M.D. (he/him) Senior Scientific Advisor 6707 Democracy Blvd. Room # 6121, MSC 5458 Bethesda, MD 20892 Phone: 301-594-7718
	MAINTENANCE

RESULTS

Public View

Additional Criteria:

OF MIAMI

	Phase:	Early Phase 1 Phase 1 Phase 2
		Phase 3 Phase 4 Not Applicable
	Funder Type:	□ NIH □ Other U.S. Federal agency
		□ Industry □ All others (individuals, universities, organizations)
	Study Documents:	Study Protocols
		□ Statistical Analysis Plans (SAPs)
		□ Informed Consent Forms (ICFs)
	FDAAA 801 Violations:	
	Results Submitted:	✓ x
	Study Start:	From x To x (MM/DD/YYYY)
	Primary Completion:	From x To x (MM/DD/YYYY)
	First Posted:	From x To x (MM/DD/YYYY)
	Results First Posted:	From x To x (MM/DD/YYYY)
	Last Update Posted:	From x To x (MM/DD/YYYY)
		Search Help Sort studies by: Relevance V
UNIVERSITY		

Public View

Sponsor:

University Hospitals Cleveland Medical Center

Information provided by (Responsible Party):

Andrey Petrikovets, Case Western Reserve University

Study Details	Tabular	View Study Resu	Its FDAAA 801 V	iolations Disclaim	er 💽 How to F	Read a Study Record
Information on FDAAA 801 Violations () More Info						More Information: Notices of Noncompliance [FDA]
Available on Clinical Trials.ge		vailable on ClinicalTrials.gov	Issued by FDA Study Record Submitted		Notice Type	FDAAA 801 Notice
	J	anuary 6, 2022	December 20, 2021	October 3, 2021	Correction Confirmed by FDA	The responsible party has corrected the violation.
	S	September 3, 2021	August 31, 2021	December 15, 2018	Violation Identified by FDA	Failure to Submit. The entry for this clinical trial was not complete at the time of submission, as required by law. This may or may not have any bearing on the accuracy of the information in the entry.





Civil Penalties Assessed by FDA

Non-Compliance of ClinicalTrials.gov Records

Yolanda Davis Director, Clinical Research OVPRS


How FDA Identifies Non-Compliant Studies

FDA Bioresearch Monitoring Information (BIMO)

Evaluations of Complaints Received



What Generates a Non-Compliance Notice





What Amount are you Assessed?





Open Forum Questions



